Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern.
García-Pérez J, Bermejo M, Ramírez-García A, De La Torre-Tarazona HE, Cascajero A, Castillo de la Osa M, Jiménez P, Aparicio Gómez M, Calonge E, Sancho-López A, Payares-Herrera C, Layunta Acero R, Vicente-Izquierdo L, Avendaño-Solá C, Alcamí J, Pérez-Olmeda M, Díez-Fuertes F. García-Pérez J, et al. Among authors: cascajero a. J Med Virol. 2023 Mar;95(3):e28679. doi: 10.1002/jmv.28679. J Med Virol. 2023. PMID: 36929737
Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.
De La Torre-Tarazona E, González-Robles A, Cascajero A, Jiménez P, Miró JM, Sánchez-Palomino S, Alcamí J, Buzón MJ, García-Pérez J; Hospital Clinic HIV Investigators. De La Torre-Tarazona E, et al. Among authors: cascajero a. J Med Virol. 2023 Feb;95(2):e28543. doi: 10.1002/jmv.28543. J Med Virol. 2023. PMID: 36727646 Free article.
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group. Borobia AM, et al. Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25. Lancet. 2021. PMID: 34181880 Free PMC article. Clinical Trial.
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
Lozano-Rodríguez R, Valentín-Quiroga J, Avendaño-Ortiz J, Martín-Quirós A, Pascual-Iglesias A, Terrón-Arcos V, Montalbán-Hernández K, Casalvilla-Dueñas JC, Bergón-Gutiérrez M, Alcamí J, García-Pérez J, Cascajero A, García-Garrido MÁ, Balzo-Castillo ÁD, Peinado M, Gómez L, Llorente-Fernández I, Martín-Miguel G, Herrero-Benito C, Benito JM, Rallón N, Vela-Olmo C, López-Morejón L, Cubillos-Zapata C, Aguirre LA, Fresno CD, López-Collazo E. Lozano-Rodríguez R, et al. Among authors: cascajero a. Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21. Cell Rep. 2022. PMID: 34986327 Free PMC article.
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Garcia-Perez J, Staropoli I, Azoulay S, Heinrich JT, Cascajero A, Colin P, Lortat-Jacob H, Arenzana-Seisdedos F, Alcami J, Kellenberger E, Lagane B. Garcia-Perez J, et al. Among authors: cascajero a. Retrovirology. 2015 Jun 18;12:50. doi: 10.1186/s12977-015-0177-1. Retrovirology. 2015. PMID: 26081316 Free PMC article.
13 results